Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Pfizer Inc (PFE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 248,710,704
  • Shares Outstanding, K 5,952,865
  • Annual Sales, $ 53,647 M
  • Annual Income, $ 11,152 M
  • 60-Month Beta 0.76
  • Price/Sales 4.57
  • Price/Cash Flow 10.07
  • Price/Book 3.85

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 0.78
  • Number of Estimates 3
  • High Estimate 0.82
  • Low Estimate 0.76
  • Prior Year 0.77
  • Growth Rate Est. (year over year) +1.30%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.34 +3.64%
on 03/08/19
43.79 -4.52%
on 03/01/19
-0.59 (-1.39%)
since 02/15/19
3-Month
39.47 +5.93%
on 01/29/19
43.79 -4.52%
on 03/01/19
-0.59 (-1.39%)
since 12/18/18
52-Week
34.32 +21.82%
on 03/26/18
46.47 -10.03%
on 12/04/18
+5.03 (+13.68%)
since 03/16/18

Most Recent Stories

More News
Bristol-Myers & Pfizer Release Phase IV Data on Eliquis

Bristol-Myers (BMY) and partner Pfizer ) announce results from the phase IV - AUGUSTUS study evaluating Eliquis (apixaban) versus vitamin K antagonists (VKAs).

CELG : 87.99 (-0.53%)
BDSI : 4.91 (-1.41%)
PFE : 41.81 (+0.07%)
BMY : 49.86 (-0.20%)
The Zacks Analyst Blog Highlights: Pfizer, Roche, Merck, Allergan and J&J

The Zacks Analyst Blog Highlights: Pfizer, Roche, Merck, Allergan and J&J

JNJ : 137.17 (-0.31%)
MRK : 81.35 (-0.27%)
AGN : 150.84 (-0.27%)
RHHBY : 33.8600 (-0.21%)
PFE : 41.81 (+0.07%)
AUGUSTUS Demonstrates Favorable Safety Results of Eliquis(R) Versus Vitamin K Antagonists in Non-Valvular Atrial Fibrillation Patients with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention

The Bristol-Myers Squibb-Pfizer Alliance today announced results from the Phase 4 AUGUSTUS trial evaluating Eliquis(R) (apixaban) versus vitamin K antagonists (VKAs) in patients...

PFE : 41.81 (+0.07%)
BMY : 49.86 (-0.20%)
Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others

Regulatory updates from J&J (JNJ), Merck (MRK), Roche (RHHBY), Pfizer (PFE) and others.

MRK : 81.35 (-0.27%)
JNJ : 137.17 (-0.31%)
LLY : 125.24 (+1.05%)
AGN : 150.84 (-0.27%)
RHHBY : 33.8600 (-0.21%)
PFE : 41.81 (+0.07%)
BMY : 49.86 (-0.20%)
Dow 30 Stock Roundup: PFE's Herceptin Biosimilar Gets FDA Nod, VZ to Launch 5G Soon

The index enjoyed an encouraging week, buoyed by strong economic data.

MSFT : 117.57 (+1.43%)
MSI : 140.50 (-0.10%)
AAPL : 188.02 (+1.02%)
VZ : 58.07 (-0.55%)
SPOT : 139.18 (-1.92%)
JPM : 107.19 (+0.60%)
XOM : 81.08 (+1.16%)
RHHBY : 33.8600 (-0.21%)
PFE : 41.81 (+0.07%)
BP : 44.24 (+0.84%)
BA : 372.28 (-1.77%)
Markets Right Now: Stocks end a wobbly day mostly lower

NEW YORK (AP) — The latest on developments in financial markets (all times local):

TLRD : 8.13 (-7.72%)
PFE : 41.81 (+0.07%)
Ocular Drug Delivery Technology Market Growing Demand and Trends 2019 to 2028

Ocular drug delivery technology is used in the treatment of ophthalmic diseases such as cataract, glaucoma, diabetic retinopathy etc. Manufactures are developing novel drug delivery technology which enables...

VRX.TO : 30.80 (-3.33%)
ALIM : 1.16 (-0.85%)
CLSD : 1.41 (-0.70%)
AGN : 150.84 (-0.27%)
NVS : 93.17 (-0.13%)
PFE : 41.81 (+0.07%)
OCUL : 4.06 (+0.25%)
Pfizer (PFE) Gains But Lags Market: What You Should Know

Pfizer (PFE) closed at $41.96 in the latest trading session, marking a +0.55% move from the prior day.

PFE : 41.81 (+0.07%)
Theravance (TBPH) Starts Dosing in Ulcerative Colitis Study

Theravance (TBPH) commences phase IIb/III study for its gut-selective pan- JAK inhibitor, TD-1473 in patients with moderately to severely active ulcerative colitis.

TBPH : 24.08 (+4.92%)
JNJ : 137.17 (-0.31%)
ABBV : 80.65 (-0.85%)
PFE : 41.81 (+0.07%)
Lilly's Cyramza Successful in Phase III First-Line NSCLC Study

Lilly's (LLY) cancer drug, Cyramza, in combination with erlotinib significantly delays disease progression in a phase III study on previously untreated patients with EGFR-mutated metastatic NSCLC.

MRK : 81.35 (-0.27%)
LLY : 125.24 (+1.05%)
RHHBY : 33.8600 (-0.21%)
PFE : 41.81 (+0.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade PFE with:

Business Summary

Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company's diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional...

See More

Key Turning Points

2nd Resistance Point 42.26
1st Resistance Point 42.03
Last Price 41.81
1st Support Level 41.62
2nd Support Level 41.43

See More

52-Week High 46.47
Fibonacci 61.8% 41.83
Last Price 41.81
Fibonacci 50% 40.40
Fibonacci 38.2% 38.96
52-Week Low 34.32

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar